사구체 기저막 항체(Anti-GBM) : 시장 인사이트, 역학 및 예측(2036년)

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Insights and Trends

• Anti-GBM disease is a rare and rapidly progressive autoimmune disorder caused by circulating autoantibodies directed against the glomerular and alveolar basement membranes, leading to severe kidney and lung injury.
• Anti-GBM disease is rare, with only about 1 in 1 million new cases being reported per year.
• Anti-GBM disease is a small-vessel vasculitis involving the kidneys (~90%) and the lungs (~60%).
• Increasing use of anti-GBM antibody testing, kidney biopsy with linear IgG deposition, and advanced renal diagnostic techniques has improved diagnostic accuracy and early disease detection, although delayed diagnosis remains common due to the rarity and rapid progression of the disease.
• Anti-GBM disease is an ultra-rare autoimmune vasculitis disorder, with an estimated incidence of approximately 0.5-1.8 cases per million population annually, contributing to substantial morbidity, mortality, and healthcare burden despite its low prevalence.
• Management of Anti-GBM disease focuses on rapid removal of circulating pathogenic antibodies, suppression of ongoing autoimmune activity, and preservation of renal and pulmonary function through intensive immunosuppressive and supportive therapies.
• Current standard therapies for Anti-GBM disease include plasma exchange (plasmapheresis), corticosteroids, and cyclophosphamide, while supportive interventions such as dialysis and ventilator support may be required in severe disease.
• The current standard of care is centered on rapid antibody removal combined with broad immunosuppression, while additional agents such as rituximab may be used in refractory patients or when cyclophosphamide is contraindicated.
• The anti-GBM disease pipeline includes emerging therapies such as imlifidase (IDEFIRIX), complement-targeted therapies, and investigational IgG-cleaving approaches aimed at improving rapid antibody clearance, renal recovery, and long-term disease control.
• Despite therapeutic advancements, anti-GBM disease continues to represent a significant unmet medical need due to delayed diagnosis, rapid disease progression, limited renal recovery in dialysis-dependent patients, lack of disease-specific approved therapies, and limited large-scale clinical evidence in this ultra-rare indication.

DelveInsight's 'Anti-Glomerular Basement Membrane (Anti-GBM) Disease - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Anti-GBM disease, historical and forecasted epidemiology, as well as the Anti-GBM disease market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Anti-GBM Disease market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Anti-GBM disease patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Anti-GBM disease and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Anti-Glomerular Basement Membrane (Anti-GBM) Disease Market

Persistent high unmet medical need due to severe disease course

Anti-GBM disease is a rare but fulminant autoimmune small-vessel vasculitis that causes rapidly progressive glomerulonephritis and often pulmonary hemorrhage. Without treatment, the disease is frequently fatal or leads to dialysis dependence. Even with current standard therapy, renal survival remains limited and outcomes are poor in a substantial proportion of patients.

Rising focus on pathogenic antibody and complement biology enabling targeted therapies

The disease is driven by autoantibodies against the a3 chain of type IV collagen in the glomerular basement membrane, leading to complement activation and severe tissue injury.

Emergence of novel mechanism-based therapies

The emergence of mechanism-based therapies in anti-GBM disease, complement inhibitors, and investigational biologics, is driving a shift from conventional broad immunosuppression toward targeted, precision immune intervention.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Understanding and Treatment Algorithm

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Overview and Diagnosis

Anti-GBM disease, also known as Goodpasture's syndrome, is a rare and rapidly progressive autoimmune disorder characterized by circulating autoantibodies against the glomerular and alveolar basement membranes, primarily affecting the kidneys and lungs. The disease commonly presents with rapidly progressive glomerulonephritis (RPGN), hematuria, proteinuria, acute kidney injury, and in some patients, pulmonary hemorrhage with hemoptysis and respiratory distress. Due to its aggressive nature, delayed treatment can lead to end-stage renal disease (ESRD) and significant mortality. Diagnosis is based on detection of circulating anti-GBM antibodies, kidney biopsy demonstrating linear IgG deposition, and assessment of renal and pulmonary involvement.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Diagnosis

Diagnosis of anti-GBM disease is primarily based on clinical evaluation, serologic testing, and kidney biopsy findings. Detection of circulating anti-GBM antibodies using enzyme-linked immunosorbent assay (ELISA) remains the key diagnostic test, while kidney biopsy demonstrating linear IgG deposition along the glomerular basement membrane by immunofluorescence is considered the diagnostic hallmark. Additional laboratory investigations, including serum creatinine, urinalysis, proteinuria assessment, and inflammatory markers, help evaluate renal involvement and disease severity. Imaging studies such as chest X-ray or CT scan may be performed in patients with suspected pulmonary hemorrhage or lung involvement.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Treatment

Treatment of Anti-GBM disease primarily focuses on rapid removal of circulating anti-GBM antibodies, suppression of ongoing autoimmune activity, and preservation of renal and pulmonary function. Standard first-line therapy includes plasma exchange (plasmapheresis) combined with high-dose corticosteroids and the immunosuppressive agent cyclophosphamide to reduce inflammation and prevent further antibody production. Patients with pulmonary hemorrhage may require intensive supportive care, including oxygen therapy and mechanical ventilation in severe cases. In refractory or relapsing disease, additional immunomodulatory therapies such as rituximab may be considered. Patients progressing to ESRD may require dialysis and, in selected cases, renal transplantation following antibody clearance

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Unmet Needs

The section "unmet needs of Anti-GBM Disease" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Need for targeted and disease-specific therapies

2. Delayed diagnosis and rapid disease progression

3. Limited renal recovery in severe and dialysis-dependent patients

4. Lack of large-scale clinical trials and standardized treatment evidence

5. Need for advanced and rapid diagnostic tools

6. Development of novel mechanism-based therapies, and others.....

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Membrane Epidemiology

Key Findings from Anti-Glomerular Basement Membrane (Anti-GBM) Disease Epidemiological Analysis and Forecast

• Anti-GBM Disease is an extremely rare but serious small vessel vasculitis and its incidence is approximately 0.5-1.8 cases per million population per year.
• Given its rarity, definitive observations regarding the incidence of Anti-GBM disease are lacking. It is often said to have an incidence of about 1 per million population per year in European populations, largely on the basis of single-center biopsy- or serology-based series, although accurately defining populations at risk in such studies is difficult.
• Anti-GBM disease has a bimodal age distribution, with peaks in the third decade (slight male preponderance) and in the sixth to seventh decades (no gender difference) and the disease in the elderly appears to take a milder course.
• Annual incidence ranged from 0.4 to 2.8 per million population per year and the average incidence over the observation period was 1.64 per million population per year.
• Anti-GBM disease most often affects men in their 20s and women in their 60s, but it can occur at any age. The condition can occur in children, but this is extremely rare.
• The highest proportion of anti-GBM disease cases occurs in females aged 30-49 years (50%), followed by those aged 49-65 years (40%), while females aged over 65 years account for 10% of cases.
• The incidence of anti-GBM disease is about 1-1.64 per million population per year.
• Anti-GBM disease has a double peak in age incidence, one in the second-third decade and one in the sixth-seventh decade. In children, 0.4% of all causes of CKD are reported to be due to anti-GBM disease.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Drug Analysis & Competitive Landscape

The Anti-GBM Disease drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Anti-GBM Disease treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the anti-GBM disease therapeutics market.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Pipeline Analysis

Veverimer: Renibus Therapeutics

Veverimer, an oral, non-absorbed hydrochloric acid binder being developed by Renibus Therapeutics, is being investigated as a potential treatment for anti-GBM disease. Unlike conventional immunosuppressive approaches, veverimer targets a complementary disease pathway by reducing renal ammoniagenesis and subsequent complement activation, which are implicated in kidney injury associated with anti-GBM disease. This differentiated mechanism may help mitigate complement-mediated renal damage and preserve kidney function. The potential of veverimer in this indication was recognized by the FDA through the granting of Orphan Drug Designation in May 2025.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Key Players, Market Leaders, and Emerging Companies

• Renibus Therapeutics

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Drug Updates

• In January 2026 corporate presentation, Hansa Biopharma discontinued the long-term follow-up phase of the Phase III GOOD-IDES-02 trial in anti-GBM disease after the core study failed to meet its primary endpoint. Detailed results from the study are expected to be presented at a medical congress in 2026, providing further insights into the clinical profile of imlifidase in this indication.
• In May 2025, Renibus Therapeutics announce that they received FDA Orphan Drug Designation for veverimer anti-GBM disease, supporting the asset's development for treatment.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Market Outlook

The Anti-GBM disease market remains highly underserved, with current treatment primarily dependent on rapid initiation of plasma exchange, corticosteroids, and cyclophosphamide to suppress pathogenic autoantibody activity and preserve renal function. Despite aggressive treatment, a substantial proportion of patients progress to ESRD or require long-term dialysis, particularly those presenting with severe renal impairment or delayed diagnosis, highlighting a significant unmet medical need for more effective and targeted therapies.

The treatment landscape is gradually evolving from conventional broad immunosuppression toward mechanism-based therapeutic approaches targeting pathogenic IgG antibodies and immune-mediated tissue injury. Emerging therapies such as imlifidase (IDEFIRIX), developed by Hansa Biopharma, and represented a novel approach through rapid IgG antibody cleavage and inhibition of IgG-mediated immune responses. However, development of imlifidase in anti-GBM disease was discontinued following the failure of the pivotal Phase III GOOD IDES 02 trial (NCT05679401) to meet its primary endpoint, leading to termination of the study's long-term follow-up phase. In parallel, other investigational strategies, including rituximab, complement-targeted therapies, and novel immune-modulating approaches such as veverimer, are being explored to improve renal recovery and disease control in severe or refractory patients. Despite ongoing research efforts, there are currently no FDA-approved therapies specifically indicated for anti-GBM disease, and treatment continues to rely largely on off-label use of immunosuppressive agents in combination with standard care.

The United States is expected to represent the largest anti-GBM disease market, supported by advanced nephrology care infrastructure, improved diagnostic capabilities, and access to high-cost biologics and plasma exchange procedures.

• The Anti-GBM disease treatment landscape is gradually shifting from non-specific immunosuppression toward targeted antibody-removal and precision immune-modulating approaches.
• Patients with severe renal impairment, dialysis dependency, or pulmonary hemorrhage continue to represent a major unmet need due to limited renal recovery despite current therapy.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Anti-Glomerular Basement Membrane (Anti-GBM) Disease (2022-2036 Forecast)

The Anti-GBM disease treatment landscape consists of antibody removal therapies, immunosuppressive agents, and emerging targeted therapies aimed at controlling pathogenic autoantibody activity and preserving renal and pulmonary function.

• Antibody removal therapies: Plasma exchange (plasmapheresis) remains the standard approach for rapidly removing circulating anti-GBM antibodies from the bloodstream and is typically initiated immediately after diagnosis.
• Immunosuppressive therapies: Corticosteroids and cyclophosphamide form the backbone of treatment by reducing inflammation and suppressing further anti-GBM antibody production. Rituximab may be considered in refractory patients or in cases where cyclophosphamide cannot be used.

Overall, plasma exchange and immunosuppressive therapies continue to define the current standard of care in anti-GBM disease management, with corticosteroids and cyclophosphamide remaining essential for suppressing pathogenic antibody production and controlling immune-mediated inflammation.

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Anti-GBM Disease drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in anti-GBM disease is expected to vary across antibody removal therapies, immunosuppressive agents, and emerging targeted immune-modulating therapies. Established treatments such as plasma exchange (plasmapheresis), corticosteroids, and cyclophosphamide are anticipated to maintain strong and sustained use due to their central role in rapid antibody removal, suppression of autoimmune activity, and preservation of renal function in acute disease management. In parallel, supportive interventions including dialysis and respiratory support are expected to remain essential in patients with severe renal or pulmonary involvement.

In addition, investigational approaches including rituximab, complement-targeted therapies, and other IgG-directed therapies are being evaluated to improve disease control and renal outcomes. Their future uptake will depend on the generation of robust clinical evidence demonstrating improved efficacy, safety, renal recovery, and reduced progression to end-stage renal disease compared with conventional therapy alone.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Anti-Glomerular Basement Membrane (Anti-GBM) Disease

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report....

Anti-Glomerular Basement Membrane (Anti-GBM) Disease Therapies Price Scenario & Trends

Pricing and analogue assessment of Anti-GBM disease therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Anti-Glomerular Basement Membrane (Anti-GBM) Disease

To keep up with Anti-GBM disease market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging Anti-GBM disease therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Anti-GBM disease, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Professor, Nephrologist, etc., were contacted. Their opinion helps understand and validate current and emerging Anti-GBM disease therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Anti-GBM disease.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Anti-GBM Disease, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Anti-GBM disease, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Anti-GBM Disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Anti-GBM Disease market.

Report Insights

• Anti-GBM Disease Patient Population Forecast
• Anti-GBM Disease Therapeutics Market Size
• Anti-GBM Disease Pipeline Analysis
• Anti-GBM Disease Market Size and Trends
• Anti-GBM Disease Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Anti-GBM Disease Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Anti-GBM Disease Treatment Addressable Market (TAM)
• Anti-GBM Disease Competitive Landscape
• Anti-GBM Disease Major Companies Insights
• Anti-GBM Disease Price Trends and Analogue Assessment
• Anti-GBM Disease Therapies Drug Adoption/Uptake
• Anti-GBM Disease Therapies Peak Patient Share Analysis

Report Assessment

• Anti-GBM Disease Current Treatment Practices
• Anti-GBM Disease Unmet Needs
• Anti-GBM Disease Clinical Development Analysis
• Anti-GBM Disease Emerging Drugs Product Profiles
• Anti-GBM Disease Market Attractiveness
• Anti-GBM Disease Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the Anti-GBM disease market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Anti-GBM disease?
• What are the disease risks, burdens, and unmet needs of Anti-GBM disease? What will be the growth opportunities across the 7MM concerning the patient population with Anti-GBM disease?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Anti-GBM disease? What are the current guidelines for treating Anti-GBM disease in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Anti-GBM Disease market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of . Anti-Glomerular Basement Membrane (Anti-GBM) Disease

6. Anti-GBM Disease Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Anti-GBM Disease By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Anti-GBM Disease By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Anti-GBM

• 7.1. Introduction
• 7.2. Risk Factors and Causes of Anti-GBM disease
• 7.3. Signs and symptoms of Anti-GBM disease
• 7.4. Pathophysiology of Anti-GBM disease
• 7.5. Clinical manifestations of Anti-GBM disease
• 7.6. Complications of Anti-GBM disease
• 7.7. Diagnosis of Anti-GBM disease
• 7.8. Diagnostic Algorithm
• 7.9. Differential Diagnosis
  • 7.9.1. Diagnostic Guidelines
  • 7.9.2. Diagnostic guideline by KDIGO
  • 7.9.3. KDIGO diagnostic guideline for Kidney biopsy

8. Treatment and Guidelines

• 8.1. KDIGO Treatment Algorithm of Anti-GBM disease
• 8.2. Treatment Guidelines

9. Epidemiology and Patient Population of Anti-GBM Disease

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Total Incident Cases of Anti-GBM Disease in the 7MM
• 9.3. The US
  • 9.3.1. Total Incident Cases of Anti-GBM Disease in the US
  • 9.3.2. Total Diagnosed Cases of Anti-GBM Disease in the US
  • 9.3.3. Age-specific Incident Cases of Anti-GBM Disease in the US
  • 9.3.4. Total Treated Cases of Anti-GBM Disease in the US
• 9.4. EU4 and the UK
  • 9.4.1. Total Incident Cases of Anti-GBM Disease in EU4 and the UK
  • 9.4.2. Total Diagnosed Cases of Anti-GBM Disease in EU4 and the UK
  • 9.4.3. Age-specific Incident Cases of Anti-GBM Disease in EU4 and the UK
  • 9.4.4. Total Treated Cases of Anti-GBM Disease in EU4 and the UK
• 9.5. Japan
  • 9.5.1. Total Incident Cases of Anti-GBM Disease in the Japan
  • 9.5.2. Total Diagnosed Cases of Anti-GBM Disease in the Japan
  • 9.5.3. Age-specific Incident Cases of Anti-GBM Disease in the Japan
  • 9.5.4. Total Treated Cases of Anti-GBM Disease in the Japan

10. Patient Journey of Anti-GBM Disease

11. Emerging Therapies

• 11.1. Competitive Landscape: Emerging Therapies
• 11.2. Veverimer: Renibus Therapeutics
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst's View

12. Anti-GBM Disease: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Anti-GBM Disease in the 7MM
• 12.6. Market Size of Anti-GBM Disease by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Total Market Size of Anti-GBM Disease in the United States
  • 12.7.2. Market Size of Anti-GBM Disease by Therapies in the United States
• 12.8. EU4 and the UK
  • 12.8.1. Total Market Size of Anti-GBM Disease in EU4 and the UK
  • 12.8.2. Market Size of Anti-GBM Disease by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of Anti-GBM Disease in Japan
  • 12.9.2. Market Size of Anti-GBM Disease by Therapies in Japan

13. Unmet Needs of Anti-GBM Disease

14. SWOT Analysis of Anti-GBM Disease

15. KOL Views of Anti-GBM Disease

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Anti-GBM Disease Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight